1581752-93-3 Usage
Description
(2R,6R)-4-(tert-butoxycarbonyl)-6-MethylMorpholine-2-carboxylic acid is a chiral organic compound with the molecular formula C12H21NO5. It features a morpholine ring, a carboxylic acid, and a tert-butoxycarbonyl group, with the (2R,6R) configuration denoting its specific stereochemistry. This unique structure and the presence of functional groups make it a versatile molecule for various applications in the chemical and pharmaceutical industries.
Uses
Used in Organic Synthesis:
(2R,6R)-4-(tert-butoxycarbonyl)-6-MethylMorpholine-2-carboxylic acid is used as a building block in organic synthesis for the creation of diverse chemical compounds. Its functional groups and stereochemistry allow for the development of complex molecules with specific properties and reactivity.
Used in Pharmaceutical Industry:
(2R,6R)-4-(tert-butoxycarbonyl)-6-MethylMorpholine-2-carboxylic acid is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure and functional groups enable the design and development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
(2R,6R)-4-(tert-butoxycarbonyl)-6-MethylMorpholine-2-carboxylic acid is also used as a building block in the preparation of agrochemicals, such as pesticides and herbicides. Its stereochemistry and functional groups contribute to the development of effective and targeted agrochemicals for agricultural applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1581752-93-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,8,1,7,5 and 2 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1581752-93:
(9*1)+(8*5)+(7*8)+(6*1)+(5*7)+(4*5)+(3*2)+(2*9)+(1*3)=193
193 % 10 = 3
So 1581752-93-3 is a valid CAS Registry Number.
1581752-93-3Relevant articles and documents
NOVEL QUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
-
Page/Page column 19; 20, (2021/03/19)
The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
